IPO registrations (S-1, F-1) · Registrants
ZyVersa Therapeutics, Inc.
- SEC CIK
- 1859007 · filings on EDGAR ↗
- Former names
- Larkspur Health Acquisition Corp. (2021–2022)
- Registration
- Form S-1, first filed 2021-05-13, last 2025-08-01; 6 initial registrations, 21 amendments
- Outcome
- Final prospectus filed 2021-12-22; declared effective 2021-12-20
- Industry (SIC)
- Pharmaceutical Preparations 2834
- Incorporated in
- DE
- Business address
- 2436 NORTH FEDERAL HIGHWAY, SUITE 466, Lighthouse Point, FL 33064
- EIN
- 86-2685744
- Ticker
- ZVSA (OTC)
- EDGAR entity type
- operating
- Insiders and CEO pay
- ZyVersa Therapeutics, Inc. on the corporate pages
Offering terms
- Final price
- $10.00 per share (424B4 filed 2021-12-22, an initial public offering)
- Shares sold
- 7,500,000
- Gross proceeds
- $75,000,000 before underwriting discounts and any over-allotment option
- Listing
- Nasdaq under the symbol LSPR
- Lead underwriters
- A.G.P./Alliance Global Partners; The Benchmark Company
- Syndicate
- J.P. Morgan; Brookline Capital Markets
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
On this site
- Business registration: ZYVERSA THERAPEUTICS, INC. EXACT (EIN (EXACT, as the state registration reports it))
- SEC filer: Larkspur Health Acquisition Corp. EXACT (CIK (EXACT))
- Person page: Dr Pablo A Guzman Fuzzy (officer, director or 10% owner on the company's Forms 3, 4 and 5 (Officer))
- Person page: Robert G Finizio Fuzzy (officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director))
Filings 44
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2021-05-13 | S-1 | S-1 (registration) | Larkspur Health Acquisition Corp. | 0001213900-21-025890 ↗ |
| 2021-06-21 | S-1/A | S-1/A (amendment) | Larkspur Health Acquisition Corp. | 0001213900-21-033318 ↗ |
| 2021-07-07 | S-1/A | S-1/A (amendment) | Larkspur Health Acquisition Corp. | 0001213900-21-035978 ↗ |
| 2021-07-27 | S-1/A | S-1/A (amendment) | Larkspur Health Acquisition Corp. | 0001213900-21-038935 ↗ |
| 2021-09-17 | S-1/A | S-1/A (amendment) | Larkspur Health Acquisition Corp. | 0001213900-21-048448 ↗ |
| 2021-11-08 | S-1/A | S-1/A (amendment) | Larkspur Health Acquisition Corp. | 0001213900-21-057114 ↗ |
| 2021-12-07 | S-1/A | S-1/A (amendment) | Larkspur Health Acquisition Corp. | 0001213900-21-063736 ↗ |
| 2021-12-20 | EFFECT | EFFECT (declared effective) | Larkspur Health Acquisition Corp. | 9999999995-21-004755 ↗ |
| 2021-12-22 | 424B4 | 424B4 (final prospectus) | Larkspur Health Acquisition Corp. | 0001213900-21-066882 ↗ |
| 2022-02-11 | 424B4 | 424B4 (final prospectus) | Larkspur Health Acquisition Corp. | 0001213900-22-007007 ↗ |
| 2022-11-14 | EFFECT | EFFECT (declared effective) | Larkspur Health Acquisition Corp. | 9999999995-22-003289 ↗ |
| 2022-12-21 | S-1 | S-1 (registration) | ZyVersa Therapeutics, Inc. | 0001493152-22-036164 ↗ |
| 2023-01-27 | S-1 | S-1 (registration) | ZyVersa Therapeutics, Inc. | 0001493152-23-002767 ↗ |
| 2023-02-01 | S-1/A | S-1/A (amendment) | ZyVersa Therapeutics, Inc. | 0001493152-23-003308 ↗ |
| 2023-02-13 | S-1/A | S-1/A (amendment) | ZyVersa Therapeutics, Inc. | 0001493152-23-004396 ↗ |
| 2023-04-05 | S-1/A | S-1/A (amendment) | ZyVersa Therapeutics, Inc. | 0001493152-23-010889 ↗ |
| 2023-04-12 | S-1/A | S-1/A (amendment) | ZyVersa Therapeutics, Inc. | 0001493152-23-011896 ↗ |
| 2023-04-18 | S-1/A | S-1/A (amendment) | ZyVersa Therapeutics, Inc. | 0001493152-23-012648 ↗ |
| 2023-04-24 | S-1/A | S-1/A (amendment) | ZyVersa Therapeutics, Inc. | 0001493152-23-013293 ↗ |
| 2023-04-26 | EFFECT | EFFECT (declared effective) | ZyVersa Therapeutics, Inc. | 9999999995-23-001055 ↗ |
| 2023-04-28 | 424B4 | 424B4 (final prospectus) | ZyVersa Therapeutics, Inc. | 0001493152-23-014638 ↗ |
| 2023-06-15 | S-1 | S-1 (registration) | ZyVersa Therapeutics, Inc. | 0001493152-23-021322 ↗ |
| 2023-06-30 | S-1/A | S-1/A (amendment) | ZyVersa Therapeutics, Inc. | 0001493152-23-023162 ↗ |
| 2023-07-07 | S-1/A | S-1/A (amendment) | ZyVersa Therapeutics, Inc. | 0001493152-23-023968 ↗ |
| 2023-07-18 | EFFECT | EFFECT (declared effective) | ZyVersa Therapeutics, Inc. | 9999999995-23-002122 ↗ |
| 2023-07-26 | 424B4 | 424B4 (final prospectus) | ZyVersa Therapeutics, Inc. | 0001493152-23-025607 ↗ |
| 2023-10-05 | S-1/A | S-1/A (amendment) | ZyVersa Therapeutics, Inc. | 0001493152-23-036393 ↗ |
| 2023-10-17 | S-1/A | S-1/A (amendment) | ZyVersa Therapeutics, Inc. | 0001493152-23-037493 ↗ |
| 2023-10-20 | EFFECT | EFFECT (declared effective) | ZyVersa Therapeutics, Inc. | 9999999995-23-003031 ↗ |
| 2023-11-03 | S-1 | S-1 (registration) | ZyVersa Therapeutics, Inc. | 0001493152-23-039368 ↗ |
| 2023-11-21 | S-1/A | S-1/A (amendment) | ZyVersa Therapeutics, Inc. | 0001493152-23-042336 ↗ |
| 2023-12-05 | S-1/A | S-1/A (amendment) | ZyVersa Therapeutics, Inc. | 0001493152-23-043620 ↗ |
| 2023-12-06 | S-1/A | S-1/A (amendment) | ZyVersa Therapeutics, Inc. | 0001493152-23-043877 ↗ |
| 2023-12-06 | EFFECT | EFFECT (declared effective) | ZyVersa Therapeutics, Inc. | 9999999995-23-003560 ↗ |
| 2023-12-08 | 424B4 | 424B4 (final prospectus) | ZyVersa Therapeutics, Inc. | 0001493152-23-044266 ↗ |
| 2024-07-16 | EFFECT | EFFECT (declared effective) | ZyVersa Therapeutics, Inc. | 9999999995-24-002174 ↗ |
| 2024-09-09 | EFFECT | EFFECT (declared effective) | ZyVersa Therapeutics, Inc. | 9999999995-24-002768 ↗ |
| 2024-09-09 | EFFECT | EFFECT (declared effective) | ZyVersa Therapeutics, Inc. | 9999999995-24-002769 ↗ |
| 2024-12-26 | EFFECT | EFFECT (declared effective) | ZyVersa Therapeutics, Inc. | 9999999995-24-003923 ↗ |
| 2025-04-09 | EFFECT | EFFECT (declared effective) | ZyVersa Therapeutics, Inc. | 9999999995-25-001061 ↗ |
| 2025-07-02 | S-1 | S-1 (registration) | ZyVersa Therapeutics, Inc. | 0001641172-25-017434 ↗ |
| 2025-07-18 | S-1/A | S-1/A (amendment) | ZyVersa Therapeutics, Inc. | 0001641172-25-020253 ↗ |
| 2025-08-01 | S-1/A | S-1/A (amendment) | ZyVersa Therapeutics, Inc. | 0001641172-25-021952 ↗ |
| 2025-08-06 | EFFECT | EFFECT (declared effective) | ZyVersa Therapeutics, Inc. | 9999999995-25-002497 ↗ |
Prospectus pages read 2
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 2021-12-07 | S-1/A | registration statement | $10.00 | 7,500,000 | $75,000,000 | Nasdaq LSPR | 4 | primary document; price sentence, shares headline, proceeds table, cover names 4 | document ↗ | |
| 2021-12-22 | 424B4 | final prospectus | $10.00 | 7,500,000 | $75,000,000 | Nasdaq LSPR | 4 | primary document; price sentence, shares headline, proceeds table, cover names 4 | document ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| A.G.P. / ALLIANCE GLOBAL PARTNERS CORP. | TenPercentOwner | 3 | 2021–2022 | ||
| Briones David S. | Director,Officer | Chief Financial Officer | 2 | 2021–2022 | |
| Mehra Raj | Director | 2 | 2021–2022 | ||
| O'Connor Daniel J. | Director,Officer; Director,TenPercentOwner | Chief Executive Officer | 3 | 2021–2022 | |
| Skalicky Gregory | Director | 2 | 2021–2022 | ||
| Twitty Christopher | Director | 2 | 2021–2022 | ||
| Larkspur Health LLC | TenPercentOwner | 3 | 2022 | ||
| Cashmere Karen A. | Director; Officer | Chief Commercial Officer | 4 | 2022–2025 | |
| Finizio Robert G | Director | 4 | 2022–2025 | person page Fuzzy | |
| Glover Stephen C. | Director,Officer | Chief Executive Officer | 4 | 2022–2025 | |
| LaBella Nicholas A. Jr. | Officer | Chief Scientific Officer | 2 | 2022 | |
| Park Min-Chul | Director | 4 | 2022–2025 | ||
| Wolfe Peter | Officer | Chief Financial Officer | 5 | 2022–2025 | |
| INCON Co., Ltd. | TenPercentOwner | 2 | 2022–2023 | ||
| Freitag Gregory Gene | Director | 3 | 2023–2025 | ||
| Rupalla Katrin | Director | 1 | 2023 | ||
| SAPIRSTEIN JAMES | Director | 3 | 2023–2025 | ||
| Guzman Pablo A. | Officer | Chief Medical Officer | 3 | 2023–2025 | person page Fuzzy |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| Business registration | ZYVERSA THERAPEUTICS, INC. | FL | State business registries | name and state |
| Form D issuer | Zyversa Therapeutics, Inc. | FL | Form D private offerings | name and state |
| SEC filer | ZyVersa Therapeutics, Inc. | SEC filers (EDGAR) | CIK (EXACT) | |
| Trademark owner | ZyVersa Therapeutics, Inc. | FL | Trademarks (USPTO) | name and state |
| Person page | Dr Pablo A Guzman | People (Form 990 officers, directors and employees) | officer, director or 10% owner on the company's Forms 3, 4 and 5 (Officer) | |
| Person page | Robert G Finizio | People (Form 990 officers, directors and employees) | officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director) |
Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.
Others with the same interests
SIC industry Pharmaceutical Preparations, FL first:
- SANO CORP FL
- CTT PHARMACEUTICAL HOLDINGS, INC. FL
- Inhibitor Therapeutics, Inc. FL
- GENEREX BIOTECHNOLOGY CORP FL
- BIOMOLECULAR LIFE HOLDINGS, INC. FL
- Alaunos Therapeutics, Inc. FL
- ORAGENICS INC FL
- Polomar Health Services, Inc. FL
- ACCENTIA BIOPHARMACEUTICALS INC FL
- NOMAD POWER SOLUTIONS, INC. FL
In other datasets, the same topic (Health) in FL:
- Nonprofit: 414 WELLWOMEN INC (Nonprofits (IRS Form 990))
Interests: Pharmaceutical Preparations · Health